



## **CryoLife to Present at UBS Global Life Sciences Conference**

September 14, 2009

ATLANTA, Sept. 14 /PRNewswire-FirstCall/ -- *CryoLife, Inc.* (NYSE: CRY), an implantable biological medical device and cardiovascular tissue processing company, announced today that it is scheduled to participate in the upcoming UBS Global Life Sciences Conference at the Grand Hyatt New York in New York City.

Steven G. Anderson, president and chief executive officer of CryoLife, Inc., will present Monday, September 21 at 2:00 p.m., Eastern Time.

CryoLife's live presentation may be accessed through its Web site, [www.cryolife.com](http://www.cryolife.com), on the Investor Relations page. An archived copy of the presentation will be available for 30 days on the same Web site.

### *About CryoLife*

Founded in 1984, CryoLife, Inc. is a leader in the processing and distribution of implantable living human tissues for use in cardiac and vascular surgeries throughout the U.S. and Canada. The Company's CryoValve(R) SG pulmonary human heart valve, processed using CryoLife's proprietary SynerGraft(R) technology, has FDA 510(k) clearance for the replacement of diseased, damaged, malformed or malfunctioning native or prosthetic pulmonary valves. The Company's BioGlue(R) Surgical Adhesive is FDA approved as an adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels. BioGlue is also CE marked in the European Community and approved in Canada and Australia for use in soft tissue repair. The Company's BioFoam(R) Surgical Matrix is CE marked in the European Community for use as an adjunct in the sealing of abdominal parenchymal tissues (liver and spleen) when cessation of bleeding by ligature or other conventional methods is ineffective or impractical. BIOGLUE *Aesthetic*(TM) Medical Adhesive is CE marked in the European Community for periosteal fixation following endoscopic browplasty (brow lift) in reconstructive plastic surgery and is distributed by a third party for this indication. CryoLife distributes HemoStase(TM), a hemostatic agent, in much of the U.S. for use in cardiac and vascular surgery and in the European Community and Canada for cardiac, vascular, and general surgery, subject to certain exclusions.

*For additional information about the Company, visit CryoLife's Web Site: <http://www.cryolife.com>.*

### Media Contacts:

D. Ashley Lee  
Executive Vice President, Chief Financial Officer and Chief Operating Officer  
Phone: 770-419-3355

SOURCE: CryoLife, Inc.